Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SZN-8141 for Injection
SZN-8141 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SZN-8141 Single Ascending Dose Level 1 | EXPERIMENTAL | Participants will receive a single dose of SZN-8141 for Injection |
| SZN-8141 Single Ascending Dose Level 2 | EXPERIMENTAL | Participants will receive a single dose of SZN-8141 for Injection |
| SZN-8141 Single Ascending Dose Level 3 | EXPERIMENTAL | Participants will receive a single dose of SZN-8141 for Injection |
| Name | Type | Description |
|---|---|---|
| SZN-8141 for Injection | BIOLOGICAL | SZN-8141 for Injection is a humanized antibody formulated for IVT administration |
Inclusion Criteria: * Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity * Age ≥18 years and ≤90 years old * Documented diagnosis of diabetes mellitus (type 1 or 2), as defined by the American Di...
Top 16 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| 4D Molecular Therapeutics, Inc. | FDMT | 2 | PHASE3 | 4D-150, EYELEA |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Hoffmann-La Roche | RHHBY | 6 | PHASE3 | Ranibizumab, Susvimo, RO7497372, RO7823653, Faricimab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | MK-8748 |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | Surabgene Lomparvovec |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tabirafusp tedromer |
| Alvotech | ALVO | 1 | PHASE3 | AVT29 |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 |
| BioAge Labs, Inc. | BIOA | 1 | PHASE2 | BGE-102 |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Surrozen Inc | SRZN | 1 | PHASE1 | SZN-8141 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
| Bayer | BAYRY | 1 | - | Aflibercept |
SZN-8141 is an investigational monoclonal antibody developed by Surrozen, Inc. for the treatment of diabetic macular edema (DME). It is designed to target the Frizzled receptor Fzd4. SZN-8141 is in Phase 1 clinical development and is not yet approved for any indication.
SZN-8141 is being developed for the treatment of diabetic macular edema (DME), a complication of diabetes that causes fluid accumulation in the retina. It is an investigational therapy and has not been approved for any use. Its safety and efficacy are being evaluated in a first-in-human clinical trial.
SZN-8141 targets Fzd4, a Frizzled receptor. By binding to Fzd4, the monoclonal antibody is designed to modulate Wnt signaling, a pathway involved in vascular stability and barrier function in the eye. This mechanism is being explored for its potential to treat diabetic macular edema.
SZN-8141 is being developed by Surrozen, Inc., a biotechnology company traded on the Nasdaq under the ticker symbol SRZN. Surrozen is focused on discovering and developing targeted therapeutics that modulate Wnt signaling pathways.
SZN-8141 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is a first-in-human study evaluating the drug in patients with diabetic macular edema.
SZN-8141 is being evaluated in a single Phase 1 clinical trial, NCT07817121, titled "A First-in-human Trial of SZN-8141 in Diabetic Macular Edema." The trial has a planned enrollment of 9 participants and is currently not yet recruiting. It is a controlled study.
Yes, SZN-8141 for Injection is an alternative name for SZN-8141. Both refer to the same investigational monoclonal antibody developed by Surrozen, Inc. for diabetic macular edema. The formulation is intended for injection.